2020 HIV Drug Therapy Glasgow*

Download All
October 5-8, 2020/Virtual
Get the latest new data on HIV management with a downloadable slideset, on-demand audio, and an expert analysis covering key studies from this important international conference.
Eric S. Daar, MD
Monica Gandhi, MD, MPH
Marina Klein, MD, MSc, FRCP(C)
Jean-Michel Molina, MD, PhD
Renslow Sherer, MD


Hear insights from  Renslow Sherer, MD, on some of the most important data reported at the 2020 International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2020 Virtual), including new findings on long-term 2-drug and 3-drug antiretroviral therapy, the efficacy of newer 3-drug regimens in patients with baseline NRTI resistance, the latest information on investigational HIV treatment approaches, and updates on important comoribidities in patients with HIV, including COVID-19.

Renslow Sherer, MD Released: October 22, 2020

Preliminary evidence from the open-label STAT study suggests that the 2-drug regimen DTG/3TC may be a safe and effective choice for rapid-start ART. Here’s my take on what we learned from this HIV Glasgow report.

Eric S. Daar, MD Released: December 4, 2020

In this downloadable slideset, CCO’s expert faculty members summarize key studies from this important conference, including new data on current ART options, investigational ART strategies, and comorbidities.

Monica Gandhi, MD, MPH Renslow Sherer, MD Released: October 23, 2020

Experts review new study data from HIV Glasgow 2020 on current and emerging ART options as well as comorbidity management that will affect practice for international clinicians managing HIV patient care around the world.

Marina Klein, MD, MSc, FRCP(C) Jean-Michel Molina, MD, PhD Released: November 6, 2020
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Janssen Therapeutics, Division of Janssen Products, LP

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings